Coulter Partners Top hires for Q3-2025

In the third quarter of 2025 Coulter Partners drove global executive search for a wide range of life sciences, health, and technology organizations.

We successfully placed executives for independent and VC & PE-backed firms, alongside large-cap and mid-cap public companies, filling critical roles across diverse disciplines worldwide.

CEO/ C-suite/ Board

·         CEO, Diagnostic & laboratory services (PE-backed), France

·         CEO, Small-molecule therapies (VC-backed), Italy

·         CEO, Bio-storage solutions (PE-backed), UK

·         CEO, Cell & gene therapies (VC-backed), Denmark

·         Chief Financial Officer, Medical devices (VC-backed), France

·         Chief Financial Officer, Cell therapies (Publicly listed), US

·         Chief Scientific Officer, tRNA platform company (VC-backed), US

·         Chief Scientific Officer, Protein degrader therapeutics (VC-backed), Italy

·         Chief Business Officer, Regenerative macrophage therapies (VC-backed), US

·         Chief Business Officer, Pediatric medicines (VC-backed), UK

·         Chief Operating Officer, Industry catapult (Not-for-Profit), UK

·         Chair, Contract Research Organization (Publicly listed), UK

·         Board Director, Regulatory T cells (Tregs) (VC-backed), US

·         Board Director, Small-molecule inhibitors (VC-backed), US

·         Board Director, APIs (Independently-owned), Spain

Commercial/Functional/Strategic

·         VP, Commercial Strategy International, Specialty pharma (Publicly listed), US / UK

·         Country CEO, Dental services (PE-backed), Denmark

·         Country CEO, Engineering consultancy services (PE-backed), Norway

·         Global Head of Communications, Generics (Publicly listed), UK

·         General Manager, APIs / Pharma (Family-owned), Italy

·         Country General Manager, Biopharma (Publicly listed), Australia

·         Country General Manager, Medical instrumentation (Family-owned), UK

·         Market Access Director, Specialty pharma (Independently-owned), France

·         Region Finance Director, Medical devices (PE-backed), Sweden

·         Sales Managers, Pharma capex solutions (PE-backed), US

R&D/Medical/Technical

·         SVP, Quality, Pharmaceutical services (PE-backed), Ireland

·         VP, International Regulatory Strategy, Specialty biopharma (Publicly listed), UK

·         VP, CMC, MASH therapeutics (Publicly listed), US

·         VP, Global Medical Affairs, Obesity, Top 10 global pharma (Publicly listed), Denmark / US

·         AVP, Technical Operations, Organ manufacturing (Publicly listed), US

·         Global Head Biometric Sciences, Specialty pharma (Family-owned), Switzerland

·         Global Head Toxicology Services, Laboratory services (PE-backed), Germany

·         Market Value & Evidence Lead, Specialty pharma (Family-owned), Italy

·         Head of Pharmacovigilance, Drug discovery (Publicly listed), Switzerland

·         Global R&D Director, Wound care products (PE-backed), Germany

·         Executive Medical Director, Obesity, Top 10 global pharma (Publicly listed), US

·         Industrial Director, Specialty ingredients (PE-backed), France